Pheno Therapeutics Granted FDA IND Clearance for Lead Multiple Sclerosis Therapeutic Candidate PTD802
Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PTD802, the Company’s lead therapeutic candidate. The clearance allows Pheno to proceed with a first-in-human clinical trial of PTD802 in the US.
Pheno Therapeutics Granted Clinical Trial Authorisation for Lead Multiple Sclerosis Therapeutic Candidate PTD802
Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received clinical trial authorisation (CTA) from the UK’s MHRA (Medicines and Healthcare products Regulatory Agency) for its lead candidate, PTD802.
